secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2025-12-17T23:59:59+00:00
Accession:  0001658247-25-000022
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics CMO Dana Pizzuti steps down; transitions to advisor roles with $577k severance
--------------------------------------------------------------------------------

- Dr. Dana Pizzuti steps down as CMO effective Dec 31, 2025; serves as Strategic Regulatory and Development Advisor through Mar 31, 2026.
- Severance of $577,000 (12 months base salary) plus COBRA reimbursement and up to $15,000 in legal fees.
- Advisor engagement from Apr 1, 2026 to Mar 30, 2028; $600/hour, up to 20 hours/month; equity continues to vest.
- Transition duties include EU MAA approval for paltusotine (acromegaly), Brazil submission, and SKK Japanese application.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000165824725000022/0001658247-25-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000165824725000022/crnx-20251216.htm
  HTML page:      https://secwatch.observer/filing/0001658247-25-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer